COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)					3 Months Ended		6 Months Ended
	Mar. 14, 2022	Mar. 01, 2022	Jan. 12, 2022	Jan. 02, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Jun. 30, 2022
Annual license fee										$ 10,000
Annual royalty					$ 100,000		$ 100,000
Professional fees					106,500	$ 51,467	213,048	$ 164,253
Related Party [Member]
Accounts payable					732,695		732,695		$ 537,449
Massachusetts General Hospital [Member] | Related Party [Member]
Accounts payable					28,708		$ 28,708		15,097
License Agreement [Member]
License agreement, description							the Company executed a License Agreement with MGH. Prior to the first commercial sale, the License Agreement requires the Company to pay MGH a non-refundable annual license fee of $10,000 by June 30, 2022, and on each subsequent anniversary of the Effective Date thereafter. The first non-refundable annual license fee was paid on July 1, 2022. As of June 30, 2024, the Company had yet to pay the second non-refundable license fee and is included in accounts payable, related party, on the unaudited consolidated balance sheet. Additionally, following the first commercial sale, the License agreement requires the Company to pay MGH a non-refundable annual minimum royalty in the amount of $100,000 per year within sixty days after each annual anniversary of the Effective Date. The Company has yet to generate any revenue as of June 30, 2024.
License Agreement [Member] | Massachusetts General Hospital [Member]
License agreement, description							The License Agreement additionally requires VI to pay to MGH a $1.0 million “success payment” within 60 days after the first achievement of total net sales of Product or Process equal or exceeding $100,000,000 in any calendar year and $4,000,000 within 60 days after the first achievement of total net sales of Product or Process equal to or exceeding $250,000,000 in any calendar year. The Company is also required to reimburse MGH’s expenses in connection with the preparation, filing, prosecution and maintenance of all Patent Rights. $0 and $344 of expense reimbursements were paid to MGH during the three and six months ended June 30, 2024. No expense reimbursements were paid to MGH during the three and six months ended June 30, 2023. As of June 30, 2024, $28,708 is included in accounts payable, related parties, on the unaudited consolidated balance sheet. As of December 31, 2023, $18,364 is included in accounts payable, related parties, on the consolidated balance sheet.
Percentage for royalty							1.00%
Reimbursements paid					0	0	$ 344	0
Repayment of related party debt	$ 1,000,000.0
License Agreement [Member] | Massachusetts General Hospital [Member] | Related Party [Member]
Accounts payable					28,708		28,708		18,364
Consulting Agreement [Member]
Expenses included in professional fees					0	$ 0	0	$ 24,000
Consulting Agreement [Member] | Toneguzzo Ph.D [Member]
Repayment of related party debt				$ 5,000
Consulting Agreement [Member] | Related Party [Member]
Accounts payable					53,500		53,500		35,500
Consulting Agreement [Member] | Related Party [Member] | Toneguzzo Ph.D [Member]
Accounts payable					40,000		40,000		40,000
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member]
Dividends, common stock							10,000
Consulting Agreement [Member] | Donohoe Advisory Associates, LLC [Member] | Consultant [Member]
Accounts payable					1,755		1,755		1,755
Retainer fees			$ 17,500
Professional fees							10,000
Consulting Agreement [Member] | Alpha IR Group, LLC [Member]
Agreed to payment of compensation		$ 50,000
Consulting Agreement [Member] | Alpha IR Group, LLC [Member] | Related Party [Member]
Accounts payable					73,999		73,999		$ 73,999
Employment Arrangement [Member] | Chief Executive Officer and Chairman [Member]
Capital					$ 8,000,000		$ 8,000,000
Share based compensation description							(i) representing 1% of the Company’s fully diluted equity as of the payment date (the “Initial Equity Payment”) if the Company achieves a market capitalization of at least $250 million for sixty consecutive days during the Term (the “Initial Market Capitalization Target”); and (ii) representing the difference between 2% of the Company’s fully diluted equity as of the payment date and the amount of Initial Equity Payment (the “Subsequent Equity Payment” and, together with Initial Equity Payment, “Equity Payments”) if the Company achieves a market capitalization of at least $500 million for sixty consecutive days during the Term (the “Subsequent Market Capitalization Target” and, together with Initial Market Capitalization Target, “Market Capitalization Targets”), such that Mr. Pier has, in the aggregate, received shares of common stock of the Company representing 2% of the Company’s fully diluted equity as of the date of payment of Subsequent Equity Payment.
Employment Arrangement [Member] | Deferred Bonus [Member] | Chief Executive Officer and Chairman [Member]
Share based compensation							$ 100,000